Navigation Links
TREATMENT OF PRIMARY LIVER CANCER: SARAH STUDY NOW AVAILABLE FOR ALL ELIGIBLE PATIENTS THROUGHOUT FRANCE
Date:6/24/2013

nicaltrials.gov/ct2/show/NCT01482442) are currently accruing patients. The aim is to recruit 400 patients in France with the following inclusion criteria:[1]

  • Patients with advanced HCC with or without portal vein thrombosis or whose disease has progressed after chemoembolization or recurrence of HCC;
  • No extrahepatic spread;
  • Ineligible for:
    • surgical resection;
    • liver transplantation;
    • radiofrequency ablation.

There is a growing medical interest in radioembolization using yttrium-90 resin microspheres in this patient population, based on a substantial number of open-label single-group studies as well as a large multi-centre European analysis[2] of the long-term outcomes related to survival and safety of radioembolization using SIR-Spheres microspheres in patients with inoperable HCC.  

SIR-Spheres microspheres are approved for use in Australia, the European Union (CE Mark), New Zealand, Switzerland, Turkey and several other countries including in Asia (e.g. India, Korean, Singapore and Hong Kong) for the treatment of unresectable liver tumours.  SIR-Spheres microspheres are indicated in the U.S. for the treatment of unresectable metastatic liver tumors from primary colorectal cancer together with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine).

About Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) occurs in people whose livers have become severely damaged or cirrhotic, due to conditions such as hepatitis and alcoholism.  It is one o
'/>"/>

SOURCE SARAH trialists
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Pa. , Aug. 27, 2014   Auxilium Pharmaceuticals ... integrated specialty biopharmaceutical company, today announced that certain members ... Morgan Stanley Healthcare Conference to be held September 8-10, ... Adrian Adams , Chief Executive Officer and President, is ... its product portfolio at 10:55 a.m. ET on Wednesday, ...
(Date:8/27/2014)... Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received ... to initiate a Phase 1/2a clinical trial of its ... injury.  The approved trial follows the successful completion of ... is designed to assess safety and activity of escalating ... cord injuries, the first targeted indication for AST-OPC1 and ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
... IRVINE, Calif., Aug. 11, 2011 ChromaDex Corporation ... provides proprietary, science-based solutions and ingredients to the ... industries, today announced financial results for the second ... calculated in accordance with U.S. Generally Accepted Accounting ...
... 2011 Reportlinker.com announces that a ... available in its catalogue: ... - Global Opportunity Assessment, Competitive ... 2017 ...
Cached Medicine Technology:ChromaDex Announces Financial Results for Second Quarter 2011 2ChromaDex Announces Financial Results for Second Quarter 2011 3ChromaDex Announces Financial Results for Second Quarter 2011 4Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 2Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 3Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 4Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 5Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 6Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 7Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 8Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 9Disposable Hospital Supplies - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2017 10
(Date:8/27/2014)... hormone therapy has spawned a prevalent but preventable side ... flashes, according to a study by a Yale School ... study published in the Aug. 27 online issue of ... moderate to severe hot flashes also called vasomotor ... Women with VMS experience more than feeling hot; other ...
(Date:8/27/2014)... (PDT, which uses topical agents and light to kill ... common skin lesion caused by sun damage) at three ... to freeze lesions). , Author: Gayatri Patel, ... Center, in Sacramento, and colleagues. , Background: ... found on individuals with fair complexions who have had ...
(Date:8/27/2014)... Warren, MI (PRWEB) August 27, 2014 Michigan ... to help the children of a local elementary school by ... year. Siersma Elementary School has year-round attendance, and Michigan Head ... equipped to meet the new school year. , "There are ... think this is a great way to give back to ...
(Date:8/27/2014)... 2014 Dr. Stewart Shofner ... multitudes of patients suffering from impaired vision. Some of ... vision correction surgery . Recently, Dr. Shofner has noticed ... an eye exam and also online. To help patients ... myths about glaucoma. , 1)    Myth: People with perfect vision ...
(Date:8/27/2014)... Washington, New York (PRWEB) August 27, 2014 ... dedicated to protecting the rights of victims injured by ... new rules in place for discovery procedures, specifically Collection ... brought over C.R. Bard’s transvaginal mesh devices. (MDL No. ... Products Liability Litigation, the United States District Court, Southern ...
Breaking Medicine News(10 mins):Health News:The high cost of hot flashes: Millions in lost wages preventable 2Health News:Photodynamic therapy vs. cryotherapy for actinic keratoses 2Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4
... for Gerontology in Higher Education (AGHE) the educational ... will hold its 37th Annual Meeting and Educational Leadership ... Hilton Cincinnati Netherland Plaza in Cincinnati, OH. Media ... This conference provides a forum for professionals in the field ...
... , THURSDAY, Feb. 24 (HealthDay News) -- Fewer men ... (PSA) screening for prostate cancer since the release of guidelines ... few years ago, say researchers. This study examined ... decline in PSA screening was three percent among men aged ...
... University of Maryland-led team of scientists indicate that a ... antibody or a scorpion anti-malarial toxin could be ... combating malaria, at a time when the effectiveness of ... a study published in the February 25 issue of ...
... Administration and Georgetown University Medical Center (GUMC) today announced ... ethics, education, and training. The partnership enhances the capabilities ... improving public health. "We are excited about this ... goal of translating basic research discoveries into real world ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, Feb. ... the immune systems of HIV patients and may stave off ... to recommend the drug for this purpose, the findings of ... drugs that can help adjust the immune response in HIV ...
... donor-liver distribution network developed by University of Pittsburgh researchers ... receiving the transplants they need. The team reports ... donor livers currently are doled out to 11 national ... demographics, an arrangement that prevents many livers from getting ...
Cached Medicine News:Health News:As America's senior population grows, meeting to outline effective education about aging 2Health News:PSA Screening for Prostate Cancer Dips in Large U.S. Health Network 2Health News:New study shows ability of transgenic fungi to combat malaria and other bug-borne diseases 2Health News:New study shows ability of transgenic fungi to combat malaria and other bug-borne diseases 3Health News:New study shows ability of transgenic fungi to combat malaria and other bug-borne diseases 4Health News:FDA and Georgetown University Medical Center announce partnership 2Health News:Statins Might Help HIV Patients, Study Suggests 2Health News:Redesign of US donor-liver network could boost transplants by several hundred per year 2Health News:Redesign of US donor-liver network could boost transplants by several hundred per year 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: